Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Download in electronic PDF format for $75
Abstract: Eosinophilic esophagitis is a clinicopathologic disease isolated to the esophagus. It is caused by immunologic reactions to ingested and inhaled allergans. Symptoms include regurgitation, vomiting, pain, anorexia, and dysphagia. Endoscopy with biopsy is currently the only reliable diagnostic test for eosinophilic esophagitis. The disease should remit with treatments of dietary exclusion, topical corticosteroids, or both. Oral viscous budesonide is one of the promising options of topical corticosteroid to treat eosinophilic esophagitis. Since there are no commercial medicines of oral viscous budesonide, it is solely a compounded medication. This article briefly discusses the properties of the disease and covers a few compounding possibilities to oral viscous budesonide.
Related Keywords:
eosinophilic esophagitis, esophagus, immunologic reaction, allergens, dietary restrictions, topical administration, oral gel, viscous budesonide, topical corticosteroid, steroid gel, formulation
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Zur Eyal
|
Jul/Aug 2012
Pg. 288-293
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Budesonide 0.0.25% Mucoadhesive Gel
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 323
|
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
|
Sep/Oct 2019
Pg. 376-381
|
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Allen Loyd V Jr
|
May/Jun 2015
Pg. 243
|
Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
|
May/Jun 2004
Pg. 206-209
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
Budesonide 1-mg//10-mL Mucolox Oral Suspensions
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 317
|
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Israel Alan
|
May/Jun 2003
Pg. 176-178
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Women's Oral Health: Is There a Hormonal Link?
Preckshot John
|
Jan/Feb 2004
Pg. 10-14
|
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja, Krämer Irene, Kamin Wolfgang
|
May/Jun 2013
Pg. 254-261
|
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Allen Loyd V Jr
|
Sep/Oct 2024
Pg. 400
|
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Allen Loyd V Jr
|
Nov/Dec 2024
Pg. 486
|
Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
|
Nov/Dec 2012
Pg. 462-469
|
Curcumin 2% Topical Gel
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 509
|
Anhydrous Silicon Base Topical Gel Vehicle
Allen Loyd V Jr
|
May/Jun 2018
Pg. 232
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Return to Top |